Evaluating and improving orphan drug regulations in Europe: A Delphi policy study

Health Policy

Volumn 108, Issue 1, 2012, Pages 1-9

  Picavet, Eline ^a   Cassiman, David ^b   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Delphi techniques; Health policies; Orphan drugs; Rare diseases

Indexed keywords

ORPHAN DRUG;

ARTICLE; DELPHI STUDY; DRUG LEGISLATION; EUROPE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HUMAN; MEDICAL EXPERT;

DELPHI TECHNIQUE; DRUG AND NARCOTIC CONTROL; EUROPEAN UNION; HEALTH POLICY; HUMANS; ORPHAN DRUG PRODUCTION; PROGRAM EVALUATION;

EID: 84867328354     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2012.08.023     Document Type: Article

References (47)

1. European Commission. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000;L18:1-5.
2. Shah R.R. Regulatory framework for the treatment of orphan diseases. Fabry disease: perspectives from 5 years of FOS 2006, Oxford Pharma Genesis, Oxford. A. Mehta, M. Beck, G. Sunder-Plassmann (Eds.).
3. Grienenberger A. Understanding orphan drug regulations: an EU and U.S. comparative analysis. Journal of BioLaw and Business 2004, 7:58-61.
4. Faden L.B., Kaitin K.I. Assessing the performance of EMEA's centralized procedure: a comparative analysis with the US FDA. Drug Information Journal 2008, 42:45-56.
5. Liu B.C., He L., He G., He Y. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Journal of Public Health Policy 2010, 31:407-420.
6. The United States Congress. The Orphan Drug Act; 1983.
7. Garcia A.L. Is the copy better than the original? The Regulation of Orphan Drugs: a US-EU comparative perspective. Food and Drug Law 2003.
8. Westermark K., Holm B.B., Soderholm M., Llinares-Garcia J., Riviere F., Aarum S., et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nature Reviews Drug Discovery 2011, 10:341-349.
9. Denis A, Simoens S, Fostier C, Mergaert L, Cleemput I. Beleid voor zeldzame ziekten en Weesgeneesmiddelen KCE reports 112A. ; 2010. http://kce.fgov.be/sites/default/files/page_documents/d20091027330.pdf.
10. Wellman-Labadie O., Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?. Health Policy 2010, 95:216-228.
11. McCabe C., Claxton K., Tsuchiya A. Orphan drugs and the NHS: should we value rarity?. BMJ 2005, 331:1016-1019.
12. Desser A.S., Gyrd-Hansen D., Olsen J.A., Grepperud S., Kristiansen I.S. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40-67. BMJ 2010, 341:c4715.
13. de Loe R.C. Exploring complex policy questions using the policy Delphi. A multi-round, interactive survey method. Applied Geography 1995, 15:53-68.
14. Powell C. The Delphi technique: myths and realities. Journal of Advanced Nursing 2003, 41:376-382.
15. Turoff M. The Policy Delphi. ; 2002. http://is.njit.edu/pubs/delphibook/ch3b1.pdf.
16. More S.J., McKenzie K., O'Flaherty J., Doherty M.L., Cromie A.R., Magan M.J. Setting priorities for non-regulatory animal health in Ireland: results from an expert policy Delphi study and a farmer priority identification survey. Preventive Veterinary Medicine 2010, 95:198-207.
17. Anderson C. Presenting and evaluating qualitative research. American Journal of Pharmaceutical Education 2010, 74:141.
18. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nature Reviews Drug Discovery 2010, 9:921-929.
19. The European Medicines Agency: general information for sponsors of orphan medicinal products. ; 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003967.pdf.
20. Regnstrom J., Koenig F., Aronsson B., Reimer T., Svendsen K., Tsigkos S., et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. European Journal of Clinical Pharmacology 2010, 66:39-48.
21. The European Medicines Agency. Guideline on clinical trials in small populations. ; 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf.
22. Mariz S., Llinares J., Westermark K. EU regulations misunderstood. BMJ 2011, 342:d136.
23. Roos J.C., Hyry H.I., Cox T.M. Orphan drug pricing may warrant a competition law investigation. BMJ 2010, 341:c6471.
24. The European Medicines Agency. Guideline on the procedure for accelerated assessment pursuant to article 14 (9) of Regulation (EC) No. 726/2004. ; 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004136.pdf.
25. U.S. Food and Drug Administration. Fast track, accelerated approval and priority review - accelerating availability of new drugs for patients with serious diseases. ; 2011. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccesstoImportantNewTherapies/ucm128291.htm.
26. Ridley D.B., Sanchez A.C. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. Lancet 2010, 376:922-927.
27. Dimitri N. The economics of priority review vouchers. Drug Discovery Today 2010, 15:887-891.
28. The European Medicines Agency. Orphan drugs and rare diseases at a glance. ; 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500069805.pdf.
29. The European Medicines Agency. Questions and answers on the compassionate use of medicines in the European Union. ; 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500069898.pdf.
30. The European Medicines Agency. Guideline on compassionate use of medicinal products, persuant to Article 83 of Regulation (EC) No. 726/2004. ; 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004075.pdf.
31. Dear J.W., Lilitkarntakul P., Webb D.J. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. British Journal of Clinical Pharmacology 2006, 62:264-271.
32. Sheridan C. EU to review rare disease drugs market exclusivity. Nature Biotechnology 2004, 22:1061.
33. Blankart C.R., Stargardt T., Schreyogg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension Fabry disease, hereditary angioedema and chronic myeloid leukaemia. Pharmacoeconomics 2011, 29:63-82.
34. Garattini S. Time to revisit the orphan drug law. European Journal of Clinical Pharmacology 2012, 68:11.
35. Michel M., Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Review of Pharmacoeconomics & Outcomes Research 2012, 12:23-29.
36. Llinares J. A regulatory overview about rare diseases. Rare Diseases Epidemiology 2010, 686:193-207.
37. Kesselheim A.S. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development. Clinical Pharmacology and Therapeutics 2009, 85:573-575.
38. The European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. ; 2005. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500017748.pdf.
39. Garcia J.L. Scientific advice for orphan drugs: critical points and perspectives. Pharmaceuticals Policy and Law 2010, 12:45-48.
40. EUTOS for CML European Treatment and Outcome study. EUTOS for CML. ; 2012. http://www.eutos.org/content/registry/.
41. Gliklich R., Leavy M. Patient registries and rare diseases. Applied Clinical Trials 2011, 20:3.
42. Liberati A. Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. European Journal of Clinical Investigation 2010, 40:69-86.
43. European Union Committee of Experts on Rare Diseases (EUCERD). 2012 Report on the state of the art of rare diseases activities in Europe - Part I: overview of rare disease activities in Europe - July 2012. ; 2012. http://www.eucerd.eu/upload/file/Reports/2012ReportStateofArtRDActivities.pdf.
44. Abbott A. Rare-disease project has global ambitions. Nature 2011, 472:17.
45. Melnikova I. Rare diseases and orphan drugs. Nature Reviews Drug Discovery 2012, 11:267-268.
46. Eurordis. CAVOD: advocating to improve patient access to orphan drugs. ; 2011. http://www.eurordis.org/content/cavod-advocating-improve-orphan-drug-access.
47. European Network for Health Technology Assessment. About EUnetHTA. ; 2011. http://www.eunethta.net/.